/
Immunology
Psoriasis
86
Pipeline Programs↗
182
Active Trials↗
139
Companies Involved↗
Psoriasis is a moderately active landscape with 86 programs across 139 companies. The most active players are Takeda, Innovent Biopharmaceutical Technology (Hangzhou) Co., LTD., SFA Therapeutics. 30 programs are in Phase 3.
Intelligence
Pipeline Metrics
Competitive Density
Pipeline Velocity
Mech. Concentration
Completion Rate
Attrition Rate
Competition
Competitive Landscape
Bubble size = clinical trials
Approved
Phase 3
Phase 2
Phase 1
Preclinical
Key Players
Top Companies Companies ranked by the number of pipeline programs they run for this disease.
Pipeline
Programs by Phase
Preclinical37
Phase 14
Phase 215
Phase 330
Approved
No programs
Analysis
Modality Breakdown
88%
Small molecule
66 of 75 classified programs — the dominant modality here.
Small molecule leads; the ring shows all 75 classified programs, each share of the total. Modality classified for 92% of 86 pipeline programs.
Analysis
Trial Status
1,177
clinical trials
Completed845 · 72%
Recruiting84 · 7%
Terminated66 · 6%
Unknown status54 · 5%
Not yet recruiting49 · 4%
Active, not recruiting45 · 4%
Other34 · 3%
Clinical Trials
Trial Activity
1177 trials
Page 1 of 79
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)